The Discipline of Precision
A Conversation with Dr. Brian Druker
Every era of medicine settles on its own metaphor, and ours has chosen precision.
The word is everywhere now. Precision oncology. Precision diagnostics. Precision medicine. It suggests a field that has learned to aim, a field that has moved beyond the blunt instruments of the past and into a more exact relationship with disease. But precision in oncology is not a destination. It is a discipline: the patient work of asking what has gone wrong in a cell, whether that wrongness is essential to the cancer, and whether the answer might be small enough to hold in a single molecule.
Dr. Brian Druker built his career inside that question.
In the latest episode of Precision Signals, I traced the arc of his life and the arc of the field he helped invent. The conversation kept returning to a simple observation: the questions he sat with thirty years ago, about targets, mechanisms, and the courage to test an unfashionable idea in humans, are the questions oncology has not finished answering.
Brian grew up in St. Paul, the youngest of four children of first-generation immigrants from Eastern Europe. His father was a chemist who held patents on printing processes used by 3M, and the expectation that one of the children would become a doctor lived more in the atmosphere than in explicit instruction. As a boy, Brian wanted to play baseball. Science, it turned out, had other plans for him.
He landed at UC San Diego for undergrad, where he worked in John Abelson’s lab purifying restriction enzymes. He stayed for medical school, then went to Barnes Hospital in St. Louis for residency, which he still describes as one of the richest learning experiences of his life.
Somewhere along the way, he wrote in a class paper that the field would only make tangible progress by understanding what distinguishes a cancer cell from a normal cell. It was the kind of sentence a student writes before knowing how long a life can be organized around a single premise. It became the thesis statement for everything that followed.
That premise eventually led him to chronic myeloid leukemia. CML was an unusual cancer in one crucial respect: its biology had a visible center. The Philadelphia chromosome produced the BCR-ABL fusion kinase, and the disease depended on that aberrant signal. If one could inhibit ABL without damaging normal cells, the logic was clean. The question was whether such a drug could exist.
The imatinib story is now told as if inevitability was hiding inside it. It was not.
Within weeks of arriving at OHSU in 1993, Brian called Nick Lydon at Ciba-Geigy and asked whether the company had anything that might inhibit ABL. Lydon said they did. Within three months, Brian had data showing he could kill leukemia cells without harming normal ones. That sentence now sounds like the beginning of a revolution. At the time, it sounded implausible enough that both Nature and Science declined the foundational paper.
The skepticism was not irrational. The dominant view held that any ATP-competitive inhibitor would shut down too many kinases in the body. Even if the biology worked, the market appeared small: perhaps 5,000 CML patients a year. For a large company, this did not look like the kind of opportunity around which one reorganized a development program.
It took five years to convince Novartis to enter clinical trials. By 1997, Brian brought his data directly to a toxicologist at the FDA. The first human trial began in 1998, restricted to Philadelphia chromosome positive patients. His first patient was a train conductor from the Oregon coast. The leukemia went into remission.
Within six months, 53 of 54 patients had responded.
Gleevec was approved in May 2001 by the FDA. It landed on the cover of Time. The life expectancy of patients with CML moved from three to five years to an 89 percent five-year survival. A disease that had carried the emotional architecture of fatalism became, for many patients, a chronic condition. The molecule then extended into gastrointestinal stromal tumors once KIT came into view, offering the first hint that a single targeted agent might cross disease boundaries when the biology was shared.
This is the part of the story the field remembers. It is also the part some have sometimes misunderstood.
Imatinib did not prove that every cancer has a single switch waiting to be turned off. It proved that, in the right disease, with the right dependency, the right molecule can rearrange the future. CML was unusually legible. The target was not merely present. It was central.
The hundred kinase inhibitors that followed imatinib produced cycles of enthusiasm and disappointment partly because oncology internalized the wrong lesson. The field treated the imatinib paradigm at the time as a template when it was also a special case. It tried to export the form without always having the underlying biology.
That distinction matters.
In most tumors, the biology is distributed, redundant, adaptive, and heterogeneous. A single lesion rarely explains the whole disease. The cancer cell sits inside tissue, immune pressure, metabolic context, and time. This is why Brian’s argument today for bolder combination strategies carries weight. Combination therapy is easy to praise and hard to do. It multiplies toxicity, development complexity, regulatory uncertainty, and commercial coordination. But some diseases will not yield to the elegance of a single molecule because their biology is not organized around a single point of failure. In that setting, precision cannot mean one target, one drug, one patient. It has to mean understanding enough of the system to intervene at more than one essential point.
The same humility should govern how we talk about genomic data. Oncology has generated a vast amount of it. The clinical gain has been real, but not proportional to the scale of sequencing. A mutation list is not a disease model. A pathway diagram is not an intervention strategy. A biomarker is not a mechanism unless the biology makes it one.
This is where the conversation turned naturally to AI.
Brian was candid about what AI can and cannot do for biology. He drew on a Jensen Huang anecdote to make a point that stayed with me: physics has fixed laws; biology does not. AI is most useful where the underlying rules are at least partly knowable. In biology, the rules are contingent, context-dependent, and often hidden behind layers of measurement error and incomplete observation.
AI will matter enormously. It will find patterns, generate hypotheses, design molecules, read images, organize literature, and compress work that used to consume whole careers. But AI cannot rescue a field from not understanding the biology it is asking the model to optimize. I always emphasize that when the training data captures proxies, the model learns proxies. If the endpoints are noisy, the model learns noise with confidence. If the disease mechanism is only partially understood, the model may accelerate motion without improving direction.
The next quarter century in oncology may be defined less by better targets or more data than by the harder work of understanding biology well enough that our tools, AI included, finally have rules to follow.
The human texture of my conversation with Brain was quite obvious near the end, in a story about a letter Brian recently received from a patient named Kevin in Jakarta. Kevin had been newly diagnosed with CML. He wrote to thank Brian for the medicine that allowed him to plan a future with his children.
That is the standard that matters.
There is a final grace note in Brian’s story. In the late 1990s, Brian was interviewed by an AP reporter who had grown accustomed to press releases announcing cancer cures that never materialized. Her notes captured a careful skepticism: nice guy, good with his patients for a researcher, but that drug is not going anywhere.
That reporter is now his wife.
It is a funny ending, but also a useful one because the skepticism was not foolish. Unfortunately, most cancer-cure stories do fail. Most early discovery breakthroughs do not survive contact with patients. I think we need skeptics because patients need us to distinguish hope from evidence.
What made imatinib different was not that it avoided skepticism but that it survived it. And that may be the best definition of precision oncology we have:
Following a biological idea far enough, and carefully enough, that it can meet a patient and still be true.